Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) announced its quarterly earnings data on Monday. The business services provider reported ($0.26) earnings per share (EPS) for the quarter, Zacks reports. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%. The business had revenue of $10.37 million during the quarter.
Interpace Biosciences Stock Performance
Shares of OTCMKTS:IDXG traded down $0.52 during midday trading on Wednesday, hitting $5.48. 1,600 shares of the stock were exchanged, compared to its average volume of 1,714. The company has a market capitalization of $30.37 million, a PE ratio of 13.70 and a beta of 0.67. Interpace Biosciences has a 52-week low of $4.95 and a 52-week high of $7.45. The business’s fifty day simple moving average is $6.40 and its two-hundred day simple moving average is $8.05.
About Interpace Biosciences
Interpace Biosciences is a molecular diagnostics company that develops and provides tests to help clinicians assess cancer risk and guide treatment decisions. Its services combine molecular analysis with pathology and related diagnostic expertise. The company’s tests focus on conditions including pancreatic cysts and thyroid nodules. Its offerings have included PancraGEN for pancreatic cyst assessment, as well as ThyGeNEXT and ThyraMIR for evaluating thyroid nodules. Interpace has also offered molecular testing for gastrointestinal cancers.
See Also
- Five stocks we like better than Interpace Biosciences
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
